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Abstract: Worldwide, invasive meningococcal disease affects about 500,000 people annually. 
Case fatality in developed countries averages 10%, and higher rates are reported in less   prosperous 
regions. According to the World Health Organization, the most important pathogenic   serogroups 
are A, B, C, W-135, X, and Y. Clinical features of invasive meningococcal disease make diag-
nosis and management difficult. Antibiotic measures are recommended for prophylaxis after 
exposure and for treatment of invasive meningococcal disease cases; however, resistant strains 
may be emerging. Vaccines are generally regarded as the best preventative measure for invasive 
meningococcal disease. Polysaccharide vaccines against serogroups A, C, W-135, and Y using 
protein conjugation technology have clear advantages over older plain polysaccharide formula-
tions without a protein component. The first quadrivalent meningococcal conjugate vaccine 
(MenACWY-D) was licensed in the US in 2005. More recently, MenACWY-CRM (Menveo®) was 
licensed in Europe, the US, the Middle East, and Latin America. MenACWY-CRM uses cross-
reactive material 197, a nontoxic mutant of diphtheria toxin, as the carrier protein. MenACWY-
CRM offers robust immunogenicity in all age groups, with a tolerability profile similar to that of 
a plain polysaccharide vaccine. Given its potential for protecting persons from infancy to old age, 
MenACWY-CRM offers the opportunity to protect broad populations against invasive meningo-
coccal disease. The most optimal strategy for use of the vaccine has to be assessed country by 
country on the basis of local epidemiology, individual health care systems, and need.
Keywords: invasive meningococcal disease, quadrivalent meningococcal conjugate vaccine, 
Neisseria meningitidis
Introduction
Neisseria meningitidis is a Gram-negative diplococcus, and humans are its only known 
reservoir. Despite advances in therapy and vaccine technologies during the late   twentieth 
century, invasive meningococcal disease (IMD) remains a global   public health chal-
lenge. Sudden-onset epidemic and sporadic septicemia and bacterial meningitis are 
the most common manifestations of IMD, although other presentations occur. The 
meningococcal polysaccharide capsule is a major virulence factor for IMD and has 
been used to distinguish approximately a dozen serogroups.1–3
Vaccines against the various meningococcal serogroups were developed during the 
twentieth century, and in the last decade novel quadrivalent conjugate vaccines against Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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serogroups A, C, W-135, and Y became available. These vac-
cines can protect against four of the five serogroups that cause 
the vast majority of IMD. We discuss the newest of these qua-
drivalent conjugate vaccines, ie, Menveo® (MenACWY-CRM) 
in the context of the clinical importance and management of 
IMD to provide a fuller picture of the potential contribution 
of this novel vaccine to public health. This review updates 
previous reviews by Cooper et al, Pace, Pace et al, and 
Deeks,4–7 providing detailed information about the clinical 
use of antibiotics for IMD and recent clinical data.
Importance and clinical 
characteristics of meningococcal 
disease
Worldwide, an estimated 500,000 cases of IMD occur 
annually, with an average mortality rate of 5%–10% in 
developed nations.1,8–10 In the European Union, case fatality 
ratios are lowest (,5%) in children 5–9 years and highest 
($20%) in the elderly. The vast majority of IMD, nearly 90% 
of typable cases, is caused by serogroups A, B, C, W-135, and 
Y. Another serogroup, X, has caused epidemics in Africa, 
and is considered by the World Health Organization to be of 
concern.1–3,9–12
The meningococcus spreads from person to person 
by respiratory droplets, which requires close contact. 
In most individuals, acquisition of meningococci leads to 
asymptomatic colonization in the nasopharynx, after which 
the bacteria are naturally cleared. Meningococcal carriage 
has a population prevalence of about 10%, which varies 
with age and in different settings. Carriage is rather low in 
young children, increases through childhood to a peak in 
19-year-olds, who have a carriage rate .20%, and declines 
in adulthood.13,14
A minority of nasopharyngeally carried meningococci, 
even among virulent strains, will cause IMD. Some individuals 
are rendered susceptible through anatomic or functional 
asplenia, inborn or acquired deficiencies of complement 
proteins, or properdin deficiency. Disease may develop quickly 
and without warning, most commonly within the first week 
of colonization.2,11,15,16 Goldschneider et al demonstrated 
the importance of humoral immunity when they showed an 
inverse correlation between the incidence of IMD and age-
related acquisition of serum bactericidal antibodies.17
Meningitis occurs in approximately half of IMD cases. 
The remaining cases are mainly bacteremia, although menin-
gococcal pneumonia, pericarditis, septic arthritis, and other 
localized infections may occur.11,16,18–20 Less usual variations 
in clinical presentation include occult bacteremia in patients 
having mild transient illness, and chronic meningococcemia 
with fever, rash, and arthritis similar to the arthritis-dermatitis 
syndrome of gonococcemia.18,21–24
Early IMD symptoms, such as fever and headache, are 
nonspecific and similar to those of any mild viral illness. Late-
stage symptoms are more distinctive, and include stiff neck, high 
fever, photophobia, and confusion. In septicemia, coagulopathy 
and a nonblanching petechial rash may occur. Shock and 
circulatory collapse may occur rapidly. In spite of prompt 
initiation of antibiotic therapy and intensive care measures, 
mortality rates remain consistent in many areas, and up to 
20% of survivors suffer from permanent long-term sequelae, 
including deafness, cognitive deficits, seizures, amputation, 
endocrinopathy, and neuropsychiatric disorders.2,11,18–20,25
Early suspicion and prompt initiation of antimicrobial 
therapy provides the best hope for IMD patients.20 Diagnosis of 
IMD involves clinical suspicion and laboratory confirmation. 
Definitive diagnosis requires isolation of the organism 
from blood, cerebrospinal fluid, or tissue.24 The sensitivity 
of bacterial culture methods may be low, and can affect 
the accuracy of clinical diagnosis as well as epidemiologic 
surveillance.2,16 Polymerase chain reaction is a more sensitive 
method for detection, particularly in persons who receive an 
antibiotic before samples are obtained for culture.11 Given 
the difficulties of early recognition, the rapid course of the 
disease, and persistent rates of disability and mortality even 
with appropriate treatment, prevention by vaccination is the 
most viable means of controlling IMD.1,4–6,18
Epidemiology of meningococcal 
disease
The incidence of IMD usually ranges from 0.2 to 5 per 
100,000 persons, although this may increase to nearly 1% 
during major epidemics. About half of all cases occur in 
infants and young children. In industrialized countries, most 
IMD is caused by serogroups B and C.9,10 Specific strains, 
Table 1 Antibiotic recommendations for treating and preventing 
invasive meningococcal disease31
Region Therapy 
recommended
Duration  
(days)
Alternative  
therapies
US Penicillin G, ampicillin,  
third-generation  
cephalosporin
5–7 Chloramphenicol,*   
meropenem,  
fluoroquinolone
Canada Penicillin G 5–7 Not specified
europe Benzyl penicillin,  
third-generation  
cephalosporin
5–7 Chloramphenicol,*   
meropenem,  
moxifloxacin
Note: *In cases of penicillin allergy.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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clonal complexes, and serogroups are associated with case 
fatality and other unwanted outcomes.23,26
In the US, the incidence of IMD varied cyclically 
during the late twentieth century, and decreased to a rate of 
0.33/100,000 population by 2007. Most cases are caused by 
serogroups B, C, or Y. Of interest, serogroup Y accounted 
for approximately 2% of cases in 1991, but more than one-
third of cases by 1998,26,27 a pattern of increase also evident 
in Columbia and Argentina, where it was accompanied by 
an increase in W-135 disease.28,29 Global travel, which brings 
carriers of various serogroups into close contact, and capsular 
switching, a mechanism involving horizontal gene transfer, 
are thought to contribute to dynamic epidemiology.1,9,30
The greatest burden of meningococcal disease occurs 
  during serogroup A epidemics in the “meningitis belt” of Sub-
Saharan Africa during the dry season.1,11 In 2009, nearly 79,000 
cases and more than 4000 deaths were reported. Serogroups 
W-135 and X have become increasingly prominent in this 
region, the latter serogroup being of concern in part because the 
incidence during outbreaks has exceeded 25 cases per 100,000. 
Serogroup W-135 emerged as an important cause of IMD 
following outbreaks during and after the 2000 and 2001 Hajj 
pilgrimages. Subsequent cases caused by the same W-135 strain 
have occurred around the world, and W-135 disease caused by 
various strains has become endemic in some areas.9,10,30
Clinical management  
and prevention of IMD
Prompt use of appropriate antibiotics reduces the expected 
case fatality of IMD from 70%–90% to 5%–10%. Treatment 
recommendations include prophylaxis after exposure to a 
confirmed case but before manifestation of clinical signs. 
The timing of prophylaxis and treatment is crucial, given the 
rapid progression and course of IMD.3,11,24,31,32
Chemoprophylaxis should be administered to all close 
contacts, including those previously vaccinated, within 
24 hours of an index case of IMD being diagnosed, because 
the rate of secondary cases is highest immediately following 
onset of the illness.11,18,33 The US Centers for Disease Control 
and Prevention defines a contact as an individual exposed to a 
household member, day care, or nursery school contact within 
7 days before the onset of illness in the index case, and anyone 
directly exposed to oral secretions.32,33 Antibiotics are intended 
to eliminate meningococci from the nasopharyngeal tract and 
can overcome the time lag ($10 days) between vaccination or 
re-exposure and the development of protective antibodies.33 
By 10–14 days after diagnosis of the index case, chemopro-
phylaxis is not recommended. Chemoprophylaxis should be 
considered for those travelling on an airplane for $8 hours 
close to an index case.34 Hajj pilgrims from the African men-
ingitis belt countries receive meningococcal chemoprophy-
laxis at the port of entry to reduce carrier rates.35 Health care 
workers need prophylaxis if they have been directly exposed 
to nasopharyngeal secretions of an active case.
Generally recommended antibiotics for chemopro-
phylaxis include rifampin, ciprofloxacin, and ceftriaxone. 
Rifampin is preferred in industrial countries, but is contrain-
dicated in pregnant women and those with liver disease or 
alcoholism. Ciprofloxacin, the drug of choice in South Africa, 
eradicates carriage, but is also contraindicated in pregnancy. 
Azithromycin generally eradicates carriage and can be used 
in areas with ciprofloxacin-resistant strains.35 Ceftriaxone can 
Table 2 Overview of published clinical studies of MenACwY-CRM in children and adolescents
Age group Immunogenicity among MenACWY- 
CRM recipients
Safety and tolerability among 
MenACWY-CRM recipients
Infants from 2 months of age* 60%–92% of two-dose and 
81%–99% of three-dose recipients had  
protective hSBA titers ($4)52
Most common reactions were injection   
site redness and irritability52
Infants from 6 months of age 86%–100% of two-dose recipients had  
protective hSBA titers ($4)54
Most common reactions were injection   
site redness and irritability54
Toddlers 86%–100% of two-dose primed and 
94%–100% of three-dose primed toddlers had  
protective hSBA titers ($4)52 
65%–100% of unprimed toddlers had  
protective hSBA titers ($4) after two doses54
Most common reactions were injection   
site redness and irritability52
Children aged 2–10 years 83%–95% of two-dose recipients had  
protective hSBA titers ($4)56
Most common reactions were injection   
site pain, headache, and irritability56
Adolescents 75%–96% of adolescents had  
protective hSBA titers ($4)58,59
Most common reactions were injection   
site pain and headache58,59
Note: *Used an adjuvant vaccine formulation.
Abbreviation: hSBA, human complement.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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be used in pregnant women and those with contraindications 
to other agents.7–35 Penicillin, tetracycline, and erythromycin 
should not be used for chemoprophylaxis.31 Research is 
needed to evaluate prophylaxis with other antibiotics, includ-
ing third-generation cephalosporins.
Although mass antibiotic prophylaxis in outbreak 
situations suppresses meningococcal carriage, it generally 
rebounds, increasing the risk of emergence of resistant 
strains. Re-emergence of meningococcal colonization may 
occur within 8–12 weeks,37 although early recolonization 
has been observed in crowded living conditions (eg, military 
communities).
Treatment recommendations in Europe and the US31 
include various antibiotics (see Table 1). One US guideline 
recommends separate empirical antimicrobial treatment, 
ie, ampicillin and aminoglycoside or cefotaxime, in suspected 
cases of bacterial meningitis in children under 1 month of age. 
A further US guideline differentiates treatment depending on 
the N. meningitidis penicillin minimal inhibitory concentration, 
recommending penicillin G or ampicillin for minimal 
inhibitory concentrations ,0.1–1.0 µg/mL. Chloramphenicol 
is recommended in cases of penicillin allergy.31 Tetracycline 
and erythromycin are contraindicated for IMD.
As an adjuvant treatment, dexamethasone can attenuate 
inflammatory responses and may decrease cerebral edema, 
increased intracranial pressure, cerebral vasculitis, and 
neural injury. However, dexamethasone treatment also 
reduces blood–brain barrier permeability, and might reduce 
penetration of antibiotics and sterilization of the cerebrospinal 
fluid, suggesting a need for further study.31
Possibility of antibiotic-resistant 
meningococcal strains
Meningococci are not particularly efficient in developing 
resistance to antibiotics, apart from the sulfonamides (.25% 
of isolates are resistant).38 Intermediate penicillin resistance 
is widespread, being 4% in the US, 23% in Sweden, and 
38% in Portugal. In Romania, 38.7% of 2007–2008 isolates 
had intermediate resistance to penicillin and 3.3% were 
resistant.39 Since the 1980s, penicillin-resistant meningococci 
have been detected in the UK, Spain, Italy, Greece, and other 
Mediterranean countries.40 Resistance has not been reported 
to extended-spectrum cephalosporins, eg, cefotaxime and 
ceftriaxone. Chloramphenicol resistance is rarely reported.
Meningococcal strains isolated during 1999–2006 in 
Dhaka, Bangladesh, were susceptible to penicillin, ampi-
cillin, chloramphenicol, ciprofloxacin, and ceftriaxone. 
  Cotrimoxazole resistance increased from 50% to 100% 
during 2002–2006. Resistance to azithromycin emerged in 
2002, and increased to 31% in 2004, but isolates collected 
in 2005–2006 were susceptible to this antibiotic.41
Among more than 75 meningococcal strains isolated in 
2000–2008 in Singapore,42 all were susceptible to rifampicin, 
but 17% had intermediate resistance and 3% were resistant 
to penicillin. Two percent were resistant to nalidixic acid, a 
quinolone. Of note, 74% of Neisseria gonorrhae isolates were 
resistant to quinolones, and ciprofloxacin use is widespread 
in Singapore.
During a 2005–2006 outbreak of IMD around New Delhi, 
India, 15.4% of isolated strains were penicillin-resistant 
and 15.4% had intermediate resistance. All isolates were 
susceptible to the third-generation cephalosporins, azithro-
mycin and rifampicin. Resistance to quinolones was very 
high at 100% for levofloxacin, 84.6% for ofloxacin, and 
65.4% for ciprofloxacin.40,43
In 2009, the emergence of ciprofloxacin-resistant menin-
gococci in the US was reported. Resistant strains isolated in 
North Dakota and Minnesota had an indistinguishable   pattern 
of pulse-field gel electrophoresis, belonged to the same clonal 
complex, and had the same multilocus sequence type ST-162 
and porA, porB, and fetA types. By active surveillance, 
additional ciprofloxacin-resistant isolates were identified in 
California in 2007.44
In a study of isolates collected in the African menin-
gitis belt, a large number were resistant to tetracycline 
and   erythromycin. Six percent of meningococcal isolates 
  collected during 2001–2005 in South Africa had intermediate 
resistance to penicillin.45
Emerging resistance to antibiotics, especially penicillin 
and fluoroquinolones, raises concerns about treatment and 
chemoprophylaxis for IMD. Although resistant strains may 
go undetected, widespread resistance seems unlikely because 
cases remain rare in the presence of routine antibiotic use 
(eg, ciprofloxacin).38
Drug-resistant N. meningitidis can potentially cause 
a global public health threat, especially in this age of 
global travel. A recent case of drug-resistant IMD in Italy 
was diagnosed in a man following a 10-day business trip 
in India with a stopover at Frankfurt airport, thus pre-
senting multiple opportunities for transmission.46 The 
meningococcal strain affecting this patient was resistant to 
ciprofloxacin, levofloxacin, and trimethoprim + sulfame-
thoxazole. Although chemoprophylaxis was initiated in a 
timely fashion, 15 adult contacts received ciprofloxacin 
and had to be offered rifampin after susceptibility testing 
was completed.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Vaccination strategies against 
meningococcal disease
The extracellular polysaccharide coat of meningococcus 
(except serogroup B) has long been known to induce 
protective antibodies. Purified polysaccharide preparations, 
both unconjugated and protein-conjugate vaccines, are 
serogroup-specific.1 Protein-conjugate vaccines based on 
capsular polysaccharides induce a T cell-dependent immune 
response, therefore immunological memory, bringing about 
elevated or booster responses to subsequent vaccine doses. 
An important advantage of many polysaccharide-protein 
conjugate vaccine formulations is their high immunogenicity 
in young children and infants; serogroup C vaccines have 
successfully been implemented into the routine infant immu-
nization calendar in many countries. These vaccines have 
reduced nasopharyngeal carriage and thereby contribute to 
herd protection.1,18,47,48
MenACWY-CRM for serogroups  
A, C, W-135, and Y
Following an extensive clinical development program in 
persons of various ages, MenACWY-CRM is currently 
approved by the US Food and Drug Administration for use in 
persons aged 2–55 years and was granted marketing autho-
rization by the European Union for all 27 member states in 
March 2010 for people aged 11 years and older.4,49 Clinical 
data have been previously reviewed by Cooper et al, Pace, 
Pace et al, and Deeks.4–7
Protein production and conjugation
MenACWY-CRM uses cross-reactive material 197 (CRM197), 
a nontoxic mutant of the diphtheria toxin, as the conjugation 
protein. This nontoxic version of diphtheria toxin does not 
need to be inactivated by formaldehyde or glutaraldehyde, 
as routinely required for use of diphtheria toxin in vaccine 
applications. Treatment of diphtheria toxin with aldehydes 
results in intramolecular and intermolecular cross-links of 
the molecule and significant epitope modifications, which 
may decrease the accessibility of amino acid residues for 
coupling of the carrier protein with polysaccharide chains. 
In CRM197, all 39 ε-amino groups of lysine residues remain 
accessible for the conjugation process.50
The preparation of the polysaccharides in MenACWY-
CRM includes fractioning of the individual oligosaccharide 
chains, which results in a population of antigens of restricted 
and well-defined medium length and eliminates very short 
chains, which may be less immunogenic. The final pool 
of   oligosaccharides is activated via reductive animation 
followed by an adipic linker bearing a terminal active ester 
to the reducing ends of the sugar chains, ensuring that the 
saccharides are orientated radially to the carrier protein. The 
conjugation process also results in a consistent degree of 
glycosylation (saccharide to protein ratio). A 0.5 mL dose of 
MenACWY-CRM contains 10 µg Men A, 5 µg each of Men C, 
Men W-135, and MenY antigens, and approximately 47 µg of 
CRM197. No adjuvant or preservative is used.32,50
Handling and storage
MenACWY-CRM is packaged as a lyophilized serogroup A 
component and a liquid component, containing serogroup C, 
W-135, and Y antigens, for reconstitution immediately before 
intramuscular administration, preferably in the upper arm. 
Misapplication, such as subcutaneous injection, may result 
in reduced immune response. The vaccine should be stored 
in the original packaging at 2°C–8°C and not frozen. The 
unreconstituted product remained within specifications when 
stored at temperatures of up to 25°C for 24 months and up to 
40°C for 6 months in stability studies. Clinical experience 
indicates that reconstitution may be facilitated if the vaccine 
is brought to room temperature and/or shaken vigorously 
during reconstitution. Although reconstituted MenACWY-
CRM should be used immediately, it may be held at or below 
25°C for up to 8 hours.4
Immunogenicity and tolerability
As observed in previous reviews,4–6 the MenACWY-CRM 
clinical research and development program included studies 
in persons aged from 2 months to 65 years. In these studies, 
clinical endpoints used accepted correlates of protection 
for meningococcal disease in a serum bactericidal assay 
using human complement (hSBA), with titers $4 being 
considered protective in persons who were seronegative prior 
to vaccination and titers $8 being used in some studies as a 
more conservative standard.4–6,17,51
Clinical trials in infants and children
Published data describing the immunogenicity and safety 
profile of MenACWY-CRM in infants supports its suitability 
for clinical use. As noted by a number of investigators, 
MenACWY-CRM is the first quadrivalent conjugate 
vaccine to provide substantial supportive evidence of 
immunogenicity in young infants.4–6,52 Pace indicates that the 
possibility to protect persons under 2 years of age against 
serogroups W-135 and Y disease is of particular importance 
in meningococcal vaccination.5,6Infection and Drug Resistance 2011:4
100
80
60
40
20
0
AC Y W-135
Serogroup
P
e
r
c
e
n
t
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
w
i
t
h
 
h
S
B
A
 
t
i
t
e
r
 
≥
 
4
MenACWY-D MenACWY-CRM
Figure 1 Percent of children aged 2–10 years with seroresponse 30 days following 
a single dose of MenACwY-D or MenACwY-CRM.
Erythema
Induration
Pain
100
80
60
40
20
0
MenACWY-D MenACWY-CRM
Vaccine
P
e
r
c
e
n
t
 
o
f
 
2
-
 
t
o
-
 
5
-
y
e
a
r
-
o
l
d
 
c
h
i
l
d
r
e
n
w
i
t
h
 
s
o
l
i
c
i
t
e
d
 
i
n
j
e
c
t
i
o
n
-
s
i
t
e
 
r
e
a
c
t
i
o
n
s
Figure  2  Percent  of  children  aged  2–5  years  reporting  solicited  injection  site 
reactions within the 7 days following a single dose of MenACwY-D (n = 684) or 
MenACwY-CRM (n = 693).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
142
Bröker et al
Preliminary data presented by Vesikari et al supported the 
tolerability and safety profile of MenACWY-CRM in infants 
as well as further development, as did published results 
describing a trial of an earlier MenACWY formulation using 
an adjuvant.4–6,51,52 One month following study vaccination in 
an open-label trial in 175 infants, approximately 80%–100% 
of those receiving MenACWY-CRM at 6 and 12 months 
of age had an hSBA titer $8 to serogroups A, C, W-135, 
and Y. In contrast, about 60%–95% of those who received 
MenACWY-CRM at 12 months of age and 50%–100% of 
those who received the vaccine at 18 months of age had 
similar titers.4–6,53 Boosting for serogroup C was evident in 
toddlers who received the monovalent serogroup C conjugate 
vaccine at 12 months of age, followed by MenACWY-CRM 
at 18 months of age.53
A preliminary report of data from the US cohort of a 
large Phase III trial conducted in infants in Latin America 
and the US indicated that MenACWY-CRM administered at 
2, 4, and 6 months of age induced robust immune responses 
considered consistent with protection. MenACWY-CRM was 
generally well tolerated in these infants.54,55
In a randomized Phase II study of 619 healthy children 
aged 2–10 years in the US, MenACWY-CRM and MPSV4 
(unconjugated quadrivalent meningococcal polysaccharide 
vaccine; Menomune®, Sanofi Pasteur Inc, Swiftwater, PA) 
were generally well tolerated and demonstrated robust 
immunogenicity. One and 12 months following vaccina-
tion,   significantly more MenACWY-CRM recipients had 
hSBA titers $4 (the primary endpoint) compared with 
MPSV4 recipients. Compared with values 1 month following 
vaccination, hSBA geometric mean titers declined against 
each serogroup by 12 months following vaccination in both 
vaccine groups. MenACWY-CRM was generally well toler-
ated, as assessed by adverse events and solicited injection 
site and systemic reactions.56
In a Phase III study conducted in 2907 children aged 
2–10 years in the US and Canada, 61%–74% of vaccinees 
had evidence of seroresponse (a four-fold rise for those 
with hSBA titers $4 at baseline or a titer $8 for those with 
titers ,4 at baseline) following a single dose of MenACWY-
CRM (see Figure 1). These values were significantly 
higher compared with the MenACWY-D comparator for 
serogroups C, W-135, and Y. In cohorts of children identified 
by age strata (2–5 years and 6–10 years), a higher propor-
tion of MenACWY-D recipients had a seroresponse to sero-
group A compared with MenACWY-CRM, while responses 
to serogroups C, W-135, and Y met predefined criteria 
for noninferiority. Injection site reactions were reported 
in 17%–39% of children receiving MenACWY-CRM, as 
were systemic reactions in 2%–14%. The safety profile of 
MenACWY-CRM was generally similar to that observed with 
MenACWY-D (see Figures 2 and 3).57
Clinical data in adolescents  
and adults
In all published studies in adolescents, MenACWY-CRM 
induced robust immune responses to serogroups A, C, W-135, 
and Y, and was generally safe and well tolerated.4–7,58–62 
  Persistence of immunogenicity has been observed for periods 
of up to 5 years in clinical trials.63
In a study in 524 adolescents, more MenACWY-CRM 
recipients had hSBA titers $4 against serogroups A, C, and Infection and Drug Resistance 2011:4
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Y compared with recipients of MPSV4, and more of those in 
the conjugate vaccine group also had evidence of an enduring 
immune response 12 months following vaccination when com-
pared with the unconjugated polysaccharide vaccine group.58
In a randomized study of 2180 adolescents who received 
MenACWY-CRM or MenACWY-D, robust immune 
responses were seen in both vaccine groups as assessed by the 
percentage of participants with hSBA titers $8 to each of the 
four serogroups. In addition, hSBA geometric mean titers to 
all serogroups were significantly higher among MenACWY-
CRM recipients than among MenACWY-D recipients.59 An 
average of 22 months after vaccination, persistent immune 
effects for all serogroups were observed among adolescents 
who had received MenACWY-CRM.60,61
A study in 1620 healthy adolescents assessed concomi-
tant use of MenACWY-CRM and Tdap (tetanus, reduced 
diphtheria, and three-component acellular pertussis vac-
cine; Boostrix™, GlaxoSmithKline, Rixensart, Belgium) and 
human papilloma virus vaccine (Gardasil™, Merck and Co, 
Whitehouse Station, NJ).62 Immune responses to MenACWY-
CRM, human papilloma virus, tetanus, and pertussis toxoids 
were similar in cohorts who received Tdap and the human 
papilloma virus vaccine concomitantly with MenACWY-
CRM197 or in a sequential dosing regimen. As expected, 
given the relationship between diphtheria toxoid and CRM197, 
antidiphtheria responses were somewhat augmented with 
concomitant administration of MenACWY-CRM and Tdap. 
Concomitant administration of Tdap with MenACWY-CRM 
and human papilloma virus vaccine resulted in slightly 
reduced antibody responses to filamentous hemagglutinin 
and pertactin, acellular pertussis antigens with no established 
correlate of protection.
Each of the quadrivalent meningococcal vaccines 
administered in the studies in adolescents was found to be 
generally well tolerated in the study population, as were the 
comparator vaccines in the Arguedas et al study.58–62 In each 
of these studies, the most commonly reported injection site 
reaction was pain and the most commonly reported systemic 
reaction was headache.
Clinical trials of MenACWY-CRM in adults included 
study participants #65 years of age.64,65 Robust immune 
responses to serogroups A, C, W-135, and Y were observed 
in the majority of adults who received MenACWY-CRM in 
these studies. Among the 1359 adults (aged 19–55 years) 
enrolled in a Phase III study in the US and randomized to 
receive MenACWY-CRM or MenACWY-D, participants in 
both vaccine groups had robust immune responses to sero-
groups A, C, W-135, and Y. Geometric mean titers were 
significantly higher among MenACWY-CRM recipients than 
in MenACWY-D recipients for all four serogroups.64
Similar results were observed in adults enrolled into a 
Phase III study in Latin America. The majority of healthy 
adults #55 years of age had robust immune responses to Men- 
ACWY-CRM and MenACWY-D. In a cohort of 326 healthy 
adults aged 56–65 years, robust immune responses were 
observed following MenACWY-CRM. In fact, those who 
received MenACWY-CRM had post vaccination hSBA 
geometric mean titers that were 1.2–5.4-fold higher for all 
four serogroups when compared with those who received 
MPSV4, the only meningococcal vaccine licensed for use in 
this age group. As observed in adolescents, MenACWY-CRM 
was generally well tolerated in adults, with a similar safety 
profile to that of MenACWY-D or MPSV4.65
Taken together, these completed clinical trials in 
adolescents and adults support the general tolerability 
and robust immunogenicity of MenACWY-CRM in this 
population. Robust immunogenicity was observed even in 
adults aged 56–65 years, a population at increased risk of 
mortality due to IMD.58–65
Discussion
MenACWY-CRM represents an important advance 
in the prevention of meningococcal disease. In many 
regions, including the US, the Middle East, Africa, and 
Europe, conjugate meningococcal vaccines, including 
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A   conjugate vaccine (MenAfriVac®) have replaced or are 
currently replacing unconjugated polysaccharide vaccines.66 
The newest of these vaccines, MenAfriVac is a novel Men-
A-TT conjugate vaccine developed specifically for the 
meningitis belt countries. It received prequalification by the 
World Health Organization and in December 2010, Burkina 
Faso became the first country to begin a nationwide cam-
paign to introduce this novel vaccine through the Meningitis 
Vaccine Project.67 Given the presence of outbreak disease 
caused by serogroups W-135 and X in the meningitis belt, the 
epidemiology of disease in this region should be monitored 
carefully.9 Another recent development in meningococcal 
vaccines is the recent licensure of MenACWY-D for infants 
as young as 9 months of age.68
Further study is needed to establish the immunogenicity 
profile of meningococcal conjugate vaccines following 
repeated vaccination with unconjugated polysaccharide 
vaccines. This information is of interest because of the well 
established observations of hyporesponsiveness following 
multiple doses of plain (unconjugated) polysaccharide 
vaccines.69
Based on the published literature, the immunogenicity 
profile of MenACWY-CRM appears somewhat different 
from that of MenACWY-D, specifically because no pub-
lished studies support the use of MenACWY-D in young 
infants or adults older than 55 years of age. The role of 
conjugation proteins is of interest in this context, and some 
studies show differential immunogenicity in Hib vaccines 
using diphtheria toxoid or CRM197 as carrier proteins.70 
Insufficient published data exist to determine whether 
carrier proteins have a meaningful impact on the clinical 
efficacy of meningococcal vaccines.49,70,71 A recent study 
in toddlers who received a booster dose of combined 
Haemophilus influenzae type B and meningococcal 
  serogroup C vaccine employing a tetanus toxoid protein 
carrier indicated that boosting was superior among chil-
dren primed with tetanus toxoid-containing vaccines.72,73 
  Similar studies have not been performed for CRM con-
jugate vaccines.
In the UK, the institution of universal vaccination against 
meningococcal serogroup C met with concerns about the 
potential for serogroup replacement.1,3,9,18,74 Because the 
second most prevalent disease-causing serogroup in the UK 
at that time was B, for which no vaccine was available, these 
concerns were potentially serious. Carriage studies showed 
that no serogroup replacement in IMD occurred after the 
serogroup C vaccine campaigns.75,76 A small but marked 
increase in serogroup Y disease has been reported in the 
UK; however, the number of cases remains low at 59 in 
2008–2009.77 A recent carriage study among university 
students indicated the potential for replacement of carriage 
strains in dormitory housing.78 Of note, increasing rates of 
serogroup Y disease have been reported in many locations 
worldwide.1–3,9,10
Meningococcal serogroup C conjugate vaccines 
reduce asymptomatic carriage, thus leading to indirect 
herd protection in the UK and the Netherlands after these 
countries mandated vaccination of infants, young children, 
and adolescents, who are an important reservoir for 
meningococcal carriage.14 Given this clinical experience, 
vaccination programs could include quadrivalent 
meningococcal vaccines for the very young, who, along 
with teenagers, have the highest risk of acquiring IMD. 
However, a reduction in carriage following universal 
conjugate vaccination policies47 has not been documented 
for additional serogroups. The first estimate of the 
effectiveness of MenACWY-D in the US was 80%–85%, 
but based only on direct protection because coverage rates 
were too low for herd protection.79 Broader vaccination 
recommendations following the approval of MenACWY-
CRM, including a booster dose for adolescents at 16 years 
of age, may result in better coverage.49 It is well recognized 
that additional study is needed to evaluated the possible 
costs and benefits to be derived from universal adolescent 
immunization against IMD.
In the future, public health specialists and policymakers 
will consider available meningococcal vaccines, including 
MenACWY-CRM in various contexts, such as universal 
infant vaccination, booster vaccination in various age groups, 
and as a travel vaccine. These considerations will likely 
include an evaluation of the benefits and risks of all possible 
vaccination policies, as well as the costs involved. Of some 
interest is IMD caused by serogroup B, which is currently 
not vaccine-preventable in most regions. With the dramatic 
reduction of IMD cases because of the successful uptake of 
vaccination and herd protection, the political will to support 
booster vaccinations to continue a low carriage rate may 
be lacking in some countries. MenACWY-CRM, like other 
quadrivalent conjugate vaccines against IMD, promises to 
provide significant public health benefits, and the advent 
of vaccines that protect against serogroup B is also neces-
sary to provide protection against the vast majority of cases 
worldwide. Further research and development efforts80–84 are 
under way to ameliorate the ongoing public health issue of 
IMD and to augment the benefits offered by existing vaccines 
such as MenACWY-CRM.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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